Industry welcomes Brexit deal that may never happen

The British pharmaceutical industry has welcomed a draft proposal, agreed by UK and European Union negotiators, detailing terms for a phased withdrawal from the EU.

Against a fast-moving backdrop of political turmoil, the Association of the British Pharmaceutical Industry (ABPI) called the text an “important step towards securing a Brexit deal.”

Chief executive Mike Thompson added: “Agreeing a transition period will mean that our members can continue to supply medicines to patients without delay or disruption come March 2019.”